ArticleCancer management and research2012
Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.
Article in Cancer management and research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 49 citations in OpenAlex.
- Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.Blood advances · 2021Trial
- Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.European journal of cancer (Oxford, England : 1990) · 2021Trial
- Review
- Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.PloS one · 2021Article
- Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Article
- Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.Oncotarget · 2017Article
- Article
- Article
- BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.Leukemia · 2015Article
- Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.Molecular genetics & genomic medicine · 2015Article
- Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.Molecular cancer therapeutics · 2014Article
- Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.Biochimica et biophysica acta · 2014Article
- Skin cancer in kidney transplant recipients.Journal of nephrology · 2014Review
- NFκB function and regulation in cutaneous T-cell lymphoma.American journal of cancer research · 2013Review
- Review
- Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous T cell lymphomas (CTCL) clinically and biologically represent a heterogeneous group of non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome being the most common subtypes. Over the last decade, new immunological and molecular pathways have been identified that not only influence CTCL phenotype and growth, but also provide targets for therapies and prognostication. This review will focus on recent advances in the development of therapeutic agents, including bortezomib, the histone deacetylase inhibitors (vorinostat and romidepsin), and pralatrexate in CTCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.